Evan Longoria’s injury a crushing blow to Rays

20 Comments

Evan Longoria might be the American League’s most indispensable player. We’re certainly about to find out now that he’s due to miss 6-8 weeks with a hamstring tear.

Longoria, the owner of a .329/.433/.561 line and 19 RBI in 23 games to start the season, was injured on a steal attempt during Monday’s game against the Mariners.

It might be a bit of an overstatement to call Longoria’s the league’s most indispensable player, considering that he’s never even finished in the top five in the MVP balloting. Longoria, though, was off to an MVP-caliber start this year, and the fact is that he’s on a team with a $65 million payroll, not the Yankees or Rangers. The Rays couldn’t afford to pay for depth over the winter.

Replacing Longoria at third base during last night’s game was Elliot Johnson, a lifetime .189/.258/.308 hitter. The Rays could also go with Jeff Keppinger there, but while he has a better stick than the alternatives, he’s still an awfully weak option as a third baseman against right-handers.

One option would be to call up Reid Brignac to play shortstop and move Sean Rodriguez to third base, giving the team it’s best defensive alignment. However, it looks like Brignac will stay in Triple-A for now, with former Tigers second baseman Will Rhymes coming up to replace Longoria. Rhymes would serve as an occasional second baseman when Ben Zobrist plays the outfield.

Another possibility: acquiring the right-handed-hitting Jose Lopez to help out at third base. Lopez was just designated for assignment by Cleveland after hitting .190 in five games during April. He hasn’t been any good these last two years, but he did impress this March and he has more upside than the alternatives.

The Rays will struggle to hit for power with Longoria out, which could lead to a Hideki Matsui promotion in a few weeks. In the meantime, Luke Scott and Matt Joyce will need to perform. Switch-hitter Ben Zobrist could hit third in between the lefties Pena and Scott.

For what it’s worth, the Rays went 19-12 with Longoria out of the lineup last year, so they did more than tread water without him. Still, he was the team’s driving force during its late push to overtake the Red Sox, hitting 17 homers and driving in 46 runs over the final two months. Life will get more difficult without him.

MLB, union resume blood testing after pandemic, lockout

Scott Taetsch-USA TODAY Sports
1 Comment

NEW YORK – In the first acknowledgment that MLB and the players’ association resumed blood testing for human growth hormone, the organizations said none of the 1,027 samples taken during the 2022 season tested positive.

HGH testing stopped in 2021 because of the COVID-19 pandemic. Testing also was halted during the 99-day lockout that ended in mid-March, and there were supply chain issues due to COVID-19 and additional caution in testing due to coronavirus protocols.

The annual public report is issued by Thomas M. Martin, independent program administrator of MLB’s joint drug prevention and treatment program. In an announcement accompanying Thursday’s report, MLB and the union said test processing is moving form the INRS Laboratory in Quebec, Canada, to the UCLA Laboratory in California.

MLB tests for HGH using dried blood spot testing, which was a change that was agreed to during bargaining last winter. There were far fewer samples taken in 2022 compared to 2019, when there were 2,287 samples were collected – none positive.

Beyond HGH testing, 9,011 urine samples were collected in the year ending with the 2022 World Series, up from 8,436 in the previous year but down from 9,332 in 2019. And therapeutic use exemptions for attention deficit hyperactivity disorder dropped for the ninth straight year, with just 72 exemptions in 2022.

Overall, the league issued six suspensions in 2022 for performance-enhancing substances: three for Boldenone (outfielder/first baseman Danny Santana, pitcher Richard Rodriguez and infielder Jose Rondon, all free agents, for 80 games apiece); one each for Clomiphene (Milwaukee catcher Pedro Severino for 80 games), Clostebol (San Diego shortstop Fernando Tatis Jr. for 80 games) and Stanozolol (Milwaukee pitcher J.C. Mejia for 80 games).

There was an additional positive test for the banned stimulant Clobenzorex. A first positive test for a banned stimulant results in follow-up testing with no suspension.